Brexucabtagene autoleucel (BA) was approved by the US Food and Drug Administration (FDA) on October 1, 2021, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy was evaluated in ZUMA-3, a single-arm multicenter study, that evaluated BA, a CD-19 directed chimeric antigen receptor (CAR) T-
104 Reached
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1008 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes
Management of Metastatic Prostate Cancer
1039 Reached5 Comments2 Likes
Pancytopenia, a rare presentation of hyperthyroidism
832 Reached2 Comments